Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eliezer Mendel Van Allen, M.D.

Co-Author

This page shows the publications co-authored by Eliezer Van Allen and Lynette Sholl.
Connection Strength

1.108
  1. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.194
  2. Interactive or static reports to guide clinical interpretation of cancer genomics. J Am Med Inform Assoc. 2018 05 01; 25(5):458-464.
    View in: PubMed
    Score: 0.190
  3. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79.
    View in: PubMed
    Score: 0.168
  4. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63.
    View in: PubMed
    Score: 0.155
  5. Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma. J Thorac Oncol. 2022 Mar 21.
    View in: PubMed
    Score: 0.062
  6. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 08; 11(8):1952-1969.
    View in: PubMed
    Score: 0.058
  7. Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.054
  8. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.053
  9. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018 04; 23(4):401-e38.
    View in: PubMed
    Score: 0.047
  10. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 07; 19(7):787-795.
    View in: PubMed
    Score: 0.043
  11. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Per Med. 2017 Jan; 14(1):37-50.
    View in: PubMed
    Score: 0.043
  12. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016 10; 18(10):1011-9.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.